Category Archives: Cell Therapy

Given the debilitating impact of COVID-19 (Coronavirus) on the Animal Stem Cell Therapy market, companies are vying opportunities to stay afloat in the market landscape. Gain access to our latest research analysis on COVID-19 associated with the Animal Stem Cell Therapy market and understand how market players are adopting new strategies to mitigate the impact of the pandemic.

Analysis of the Global Animal Stem Cell Therapy Market

Persistence Market Research (PMR) recently published a market study which provides a detailed understanding of the various factors that are likely to influence the Animal Stem Cell Therapy market in the forecast period (20XX-20XX). The study demonstrates the historical and current market trends to predict the roadmap of the Animal Stem Cell Therapy market in the coming years. Further, the growth opportunities, capacity additions, and major limitations faced by market players in the Animal Stem Cell Therapy market are discussed.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/14941

Regional Overview

Our team of analysts at PMR, trace the major developments within the Animal Stem Cell Therapy landscape in various geographies. The market share and value of each region are discussed in the report along with graphs, tables, and figures.

Competitive Outlook

This chapter of the report discusses the ongoing developments, mergers and acquisitions of leading companies operating in the Animal Stem Cell Therapy market. The product portfolio, pricing strategy, the regional and global presence of each company is thoroughly discussed in the report.

Product Adoption Analysis

The report offers crucial insights related to the adoption pattern, supply-demand ratio, and pricing structure of each product.

Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

The report covers exhaustive analysis on:

Regional analysis for Market includes

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/14941

Key Takeways Enclosed in the Report:

Queries Related to the Animal Stem Cell Therapy Market Explained:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/14941

Why Opt for Persistence Market Research?

Continued here:
World coronavirus Dispatch: Animal Stem Cell Therapy Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2036 2017 2025 - Latest Herald

Regeneus

Global Autologous Cell Therapy Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=175172&utm_source=LHN&utm_medium=888

Autologous Cell Therapy Market Region Coverage (Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East & Africa (Saudi Arabia, South Africa etc.)

Some Notable Report Offerings:

-> We will give you an assessment of the extent to which the market acquire commercial characteristics along with examples or instances of information that helps your assessment.

-> We will also support to identify standard/customary terms and conditions such as discounts, warranties, inspection, buyer financing, and acceptance for the Autologous Cell Therapy industry.

-> We will further help you in finding any price ranges, pricing issues, and determination of price fluctuation of products in Autologous Cell Therapy industry.

-> Furthermore, we will help you to identify any crucial trends to predict Autologous Cell Therapy market growth rate up to 2026.

-> Lastly, the analyzed report will predict the general tendency for supply and demand in the Autologous Cell Therapy market.

Have Any Query? Ask Our Expert@ https://www.marketresearchintellect.com/need-customization/?rid=175172&utm_source=LHN&utm_medium=888

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Autologous Cell Therapy market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Autologous Cell Therapy market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Autologous Cell Therapy Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Autologous Cell Therapy Market Size, Autologous Cell Therapy Market Growth, Autologous Cell Therapy Market Forecast, Autologous Cell Therapy Market Analysis

Our Trending Reports

AI in Education Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Articulated Robot Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read the original:
Autologous Cell Therapy Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald

The Stem Cell Therapy Market Has Witnessed Continuous Growth In The Past Few Years And Is Projected To Grow Even Further During The Forecast Period (2020-2027). The Assessment Provides A 360 View And Insights, Outlining The Key Outcomes Of The Industry. These Insights Help The Business Decision-makers To Formulate Better Business Plans And Make Informed Decisions For Improved Profitability. In Addition, The Study Helps Venture Or Private Players In Understanding The Companies More Precisely To Make Better-informed Decisions. Some Of The Prominent Key Players Covered In The Stem Cell Therapy Market Are Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Anterogen Co. Ltd., Pharmicell Co., Inc., and Stemedica Cell Technologies, Inc.

Whats Keeping Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Anterogen Co. Ltd., Pharmicell Co., Inc., and Stemedica Cell Technologies, Inc. Ahead In The Market? Benchmark Yourself With Strategic Steps And Conclusions Recently Published By Coherent Market Insights

Type Segmentation:

By Cell Source:Adult Stem CellsInduced Pluripotent Stem CellsEmbryonic Stem CellsOthersGlobal Stem Cell Therapy Market, By Application:Musculoskeletal DisordersWounds and InjuriesCancerAutoimmune disordersOthers

Consumer Traits (If Applicable)

The Stem Cell Therapy Market Study Covers Current Status, % Share, Future Patterns, Development Rate, Swot Examination, Sales Channels, To Anticipate Growth Scenarios For Years 2020-2027. It Aims To Recommend Analysis Of The Market With Regards To Growth Trends, Prospects, And Players Contribution To Market Development. The Report Size Market By 5 Major Regions, Known As, North America, Europe, Asia Pacific (Includes Asia & Oceania Separately), Middle East And Africa (Mea), And Latin America.

The Stem Cell Therapy Market Factors Described In This Report Are:-key Strategic Developments In Stem Cell Therapy Market: The Research Includes The Key Strategic Activities Such As R&d Plans, M&a Completed, Agreements, New Launches, Collaborations, Partnerships & (Jv) Joint Ventures, And Regional Growth Of The Key Competitors Operating In The Market At A Global And Regional Scale.

Key Market Features In Stem Cell Therapy Market: The Report Highlights Stem Cell Therapy Market Features, Including Revenue, Weighted Average Regional Price, Capacity Utilization Rate, Production Rate, Gross Margins, Consumption, Import & Export, Supply & Demand, Cost Bench-marking, Market Share, Cagr, And Gross Margin.

Analytical Market Highlights & Approach The Stem Cell Therapy Market Report Provides The Rigorously Studied And Evaluated Data Of The Top Industry Players And Their Scope In The Market By Means Of Several Analytical Tools. The Analytical Tools Such As Porters Five Forces Analysis, Feasibility Study, Swot Analysis, And Roi Analysis Have Been Practiced Reviewing The Growth Of The Key Players Operating In The Market.

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/2848

Table Of Contents:

Stem Cell Therapy Market Study Coverage: It Includes Major Manufacturers, Emerging Players Growth Story, Major Business Segments Of Stem Cell Therapy Market, Years Considered, And Research Objectives. Additionally, Segmentation On The Basis Of The Type Of Product, Application, And Technology.

Stem Cell Therapy Market Executive Summary: It Gives A Summary Of Overall Studies, Growth Rate, Available Market, Competitive Landscape, Market Drivers, Trends, And Issues, And Macroscopic Indicators.Stem Cell Therapy Market Production By Region Stem Cell Therapy Market Profile Of Manufacturers-players Are Studied On The Basis Of Swot, Their Products, Production, Value, Financials, And Other Vital Factors.

Key Points Covered In Stem Cell Therapy Market Report: Stem Cell Therapy Overview, Definition And Classification Market Drivers And Barriers

Stem Cell Therapy Market Competition By Manufacturers

Stem Cell Therapy Capacity, Production, Revenue (Value) By Region (2019-2027)

Stem Cell Therapy Supply (Production), Consumption, Export, Import By Region (2019-2027)

Stem Cell Therapy Production, Revenue (Value), Price Trend By Type {strip Sensors, Invasive Sensors, Ingestible Sensors, Implantable Sensors, Wearable Sensors}

Stem Cell Therapy Market Analysis By Application {hospitals, Ambulatory Surgical Centers, Diagnostic Centers}

Stem Cell Therapy Manufacturers Profiles/analysis Stem Cell Therapy Manufacturing Cost Analysis, Industrial/supply Chain Analysis, Sourcing Strategy And Downstream Buyers, Marketing Strategy By Key Manufacturers/players, Connected Distributors/traders Standardization, Regulatory And Collaborative Initiatives, Industry Road Map And Value Chain Market Effect Factors Analysis.

Get PDF Brochure Report + All Related Graphs & Charts @ https://www.coherentmarketinsights.com/insight/request-pdf/2848

Thanks For Reading This Article; You Can Also Get Individual Chapter Wise Section Or Region Wise Report Versions Like North America, Europe Or Southeast Asia Or Just Eastern Asia.

About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts US:

Mr. ShahCoherent Market Insights,1001 4th Ave,#3200 Seattle, WA 98154, U.S.Email: [emailprotected]Phone: US +1-206-701-6702/UK +44-020 8133 4027

See more here:
Impact of COVID-19 on Stem Cell Therapy Market Investment Opportunities And Forecast 2020-2027 | By Top Key Players Magellan, Medipost Co., Ltd,...

Given the debilitating impact of COVID-19 (Coronavirus) on the Canine Stem Cell Therapy market, companies are vying opportunities to stay afloat in the market landscape. Gain access to our latest research analysis on COVID-19 associated with the Canine Stem Cell Therapy market and understand how market players are adopting new strategies to mitigate the impact of the pandemic.

Analysis of the Global Canine Stem Cell Therapy Market

Persistence Market Research (PMR) recently published a market study which provides a detailed understanding of the various factors that are likely to influence the Canine Stem Cell Therapy market in the forecast period (20XX-20XX). The study demonstrates the historical and current market trends to predict the roadmap of the Canine Stem Cell Therapy market in the coming years. Further, the growth opportunities, capacity additions, and major limitations faced by market players in the Canine Stem Cell Therapy market are discussed.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/15550

Regional Overview

Our team of analysts at PMR, trace the major developments within the Canine Stem Cell Therapy landscape in various geographies. The market share and value of each region are discussed in the report along with graphs, tables, and figures.

Competitive Outlook

This chapter of the report discusses the ongoing developments, mergers and acquisitions of leading companies operating in the Canine Stem Cell Therapy market. The product portfolio, pricing strategy, the regional and global presence of each company is thoroughly discussed in the report.

Product Adoption Analysis

The report offers crucial insights related to the adoption pattern, supply-demand ratio, and pricing structure of each product.

Company Profiles

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/15550

Key Takeways Enclosed in the Report:

Queries Related to the Canine Stem Cell Therapy Market Explained:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/15550

Why Opt for Persistence Market Research?

The rest is here:
Assessing the Fallout From the Coronavirus Pandemic Value of Canine Stem Cell Therapy Market Predicted to Surpass US$ by the of 20512019-2019 -...

Allosource

Global Stem Cell Therapy Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=COD&utm_medium=002

Stem Cell Therapy Market Region Coverage (Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East & Africa (Saudi Arabia, South Africa etc.)

Some Notable Report Offerings:

-> We will give you an assessment of the extent to which the market acquire commercial characteristics along with examples or instances of information that helps your assessment.

-> We will also support to identify standard/customary terms and conditions such as discounts, warranties, inspection, buyer financing, and acceptance for the Stem Cell Therapy industry.

-> We will further help you in finding any price ranges, pricing issues, and determination of price fluctuation of products in Stem Cell Therapy industry.

-> Furthermore, we will help you to identify any crucial trends to predict Stem Cell Therapy market growth rate up to 2026.

-> Lastly, the analyzed report will predict the general tendency for supply and demand in the Stem Cell Therapy market.

Have Any Query? Ask Our Expert @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=COD&utm_medium=002

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Stem Cell Therapy market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Stem Cell Therapy market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Stem Cell Therapy Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes, Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Tags: Stem Cell Therapy Market Size, Stem Cell Therapy Market Trends, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Analysis

Read more here:
Stem Cell Therapy Market Segmentation, Application, Technology, Analysis Research Report and Forecast to 2026 - Cole of Duty

Akron Biotechnology

Global Cell Freezing Media for Cell Therapy Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=219043&utm_source=LHN&utm_medium=888

Cell Freezing Media for Cell Therapy Market Region Coverage (Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East & Africa (Saudi Arabia, South Africa etc.)

Some Notable Report Offerings:

-> We will give you an assessment of the extent to which the market acquire commercial characteristics along with examples or instances of information that helps your assessment.

-> We will also support to identify standard/customary terms and conditions such as discounts, warranties, inspection, buyer financing, and acceptance for the Cell Freezing Media for Cell Therapy industry.

-> We will further help you in finding any price ranges, pricing issues, and determination of price fluctuation of products in Cell Freezing Media for Cell Therapy industry.

-> Furthermore, we will help you to identify any crucial trends to predict Cell Freezing Media for Cell Therapy market growth rate up to 2026.

-> Lastly, the analyzed report will predict the general tendency for supply and demand in the Cell Freezing Media for Cell Therapy market.

Have Any Query? Ask Our Expert@ https://www.marketresearchintellect.com/need-customization/?rid=219043&utm_source=LHN&utm_medium=888

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Cell Freezing Media for Cell Therapy market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Cell Freezing Media for Cell Therapy market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Cell Freezing Media for Cell Therapy Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Cell Freezing Media for Cell Therapy Market Size, Cell Freezing Media for Cell Therapy Market Growth, Cell Freezing Media for Cell Therapy Market Forecast, Cell Freezing Media for Cell Therapy Market Analysis

Our Trending Reports

Solar Water Pump Systems Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Stone And Tile Adhesives & Sealants Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Excerpt from:
Cell Freezing Media for Cell Therapy Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald

Affinia Therapeutics proprietary AAV vector technology to be used in Vertexs genetic therapy efforts with focus on Duchenne muscular dystrophy, myotonic dystrophy type 1 and cystic fibrosis

BOSTON & WALTHAM, Mass.--(BUSINESS WIRE)-- Vertex PharmaceuticalsIncorporated (Nasdaq:VRTX) and Affinia Therapeutics announced today that the two companies have entered into a strategic research collaboration to engineer novel adeno-associated virus (AAV) capsids to deliver transformative genetic therapies to people with serious diseases. Affinia Therapeutics proprietary AAVSmartLibrary and associated technology provides capsids for improved tissue tropism, manufacturability and pre-existing immunity. The collaboration will leverage Affinia Therapeutics capsid engineering expertise and Vertexs scientific, clinical and regulatory capabilities to accelerate the development of genetic therapies for people affected by Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and cystic fibrosis (CF).

This collaboration with Affinia Therapeutics will enhance our existing capabilities in discovering and developing transformative therapies for people with serious diseases, said Bastiano Sanna, Executive Vice President and Chief of Cell and Genetic Therapies at Vertex. Affinia Therapeutics innovative approach to the discovery and design of AAV capsids brings yet another tool to our Vertex Cell and Genetic Therapies toolkit, and were excited to partner with them to bring together their technology platform with our research and development expertise.

At Affinia Therapeutics, were setting a new standard in genetic therapy by leveraging our platform to methodically engineer novel AAV vectors that have unique therapeutic properties, said Rick Modi, Chief Executive Officer. Vertex is an established leader in developing transformative medicines for genetic diseases and renowned for its scientific rigor. We are thankful for the scientific validation this partnership brings and look forward to working closely with them to advance life-changing, differentiated genetic therapies and make a meaningful difference to those affected by these diseases.

About the Collaboration

Under the terms of the agreement, Affinia Therapeutics will apply its vector design and engineering technologies to develop novel capsids with improved properties. The agreement provides Vertex an exclusive license under Affinia Therapeutics proprietary technology and intellectual property (IP) in DMD and DM1 with an exclusive option to license rights for CF and an additional undisclosed disease. The scope of the agreement covers all genetic therapy modalities in these diseases. Affinia Therapeutics will be eligible to receive over $1.6 billion in upfront and development, regulatory and commercial milestones, including $80 million in upfront payments and research milestones that will be paid during the research term, plus tiered royalties on future net global sales on any products that result from the collaboration. Affinia Therapeutics will be responsible for the discovery of capsids that meet certain pre-determined criteria. Vertex will be responsible for and will fund the design and manufacturing of genetic therapies incorporating the selected capsids, preclinical and clinical development efforts, and commercialization of any approved products in the licensed diseases.

About Affinia Therapeutics

At Affinia Therapeutics, our purpose is to develop gene therapies that can have a transformative impact on people affected by devastating genetic diseases. Our proprietary platform enables us to methodically engineer novel AAV vectors and gene therapies that have remarkable tissue targeting and other properties. We are building world-class capabilities to discover, develop, manufacture and commercialize gene therapy products with an initial focus on muscle and central nervous system (CNS) diseases with significant unmet need. http://www.affiniatx.com.

About Vertex Pharmaceuticals

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) a rare, life-threatening genetic disease and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London, UK. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 10 consecutive years on Science magazine's Top Employers list and top five on the 2019 Best Employers for Diversity list by Forbes. For company updates and to learn more about Vertex's history of innovation, visit http://www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, Dr. Sannas statements in the second paragraph of the press release, Mr. Modis statements in the third paragraph of the press release, and statements regarding future activities of the parties pursuant to the collaboration. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent Vertex's beliefs only as of the date of this press release and there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements. Those risks and uncertainties include, among other things, Vertex may not realize the anticipated benefits of the collaboration, and the other risks listed under Risk Factors in Vertex's annual report and quarterly reports filed with the Securities and Exchange Commission and available through the company's website at http://www.vrtx.com. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

View source version on businesswire.com: https://www.businesswire.com/news/home/20200427005151/en/

Read the rest here:
Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies -...

Chimeric antigen receptor (CAR) T-cell therapy has been shown to improve health-related quality of life in patients with relapsed/refractory diffuse large B-cell lymphoma (LBCL). Currently, CAR T-cell therapies are primarily administered in inpatient settings. In a study published in JAMA Network Open, researchers found CAR T-cell therapy administered to patients with relapsed or refractory LBCL in outpatient settings was associated with lower estimated overall costs.

In a study published in JAMA Network Open, researchers found CAR T-cell therapy administered to patients with relapsed or refractory LBCL in outpatient settings was associated with lower estimated overall costs. CAR-T cell therapies also hold promise for patients with hematologic malignant neoplasms that are unresponsive or resistant to standard treatments, researchers said.

The treatment involves harvesting and reengineering an individuals own cells to attack specific malignant cells. CAR-T cells were initially developed using knowledge gleaned from allogeneic stem cell transplantsthat donor mature immune cells can attack healthy cells in the recipient patient.

In an economic evaluation, researchers used a decision-tree model to document patient clinical outcomes and costs, using only hypothetical patients and facilities. Excluding the CAR T-cell acquisition cost, researchers found hospitalization and office visits comprised 65.3% of the costs in inpatient settings and 48.4% of the costs in outpatient settings. Specifically, outpatient administration of CAR T-cell therapy in nonacademic specialty oncology networks was associated with a $32,987 (40.4%) reduction in total costs. Sensitivity analyses were carried out to address assumptions made to build the model.

Before the approval of CAR T-cell therapy, the available treatments for patients with relapsed or refractory LBCL included high-dose chemotherapy, salvage chemotherapy, and autologous hematopoietic stem cell transplantation (auto-HSCT); however, the prognosis after these treatments is often poor, authors said.

Researchers analyzed a predefined period from lymphodepletion to 30 days after the receipt of CAR T-cell infusion, in order to account for potential incidences of adverse events. Data were collected from several sources including theHealthcare Cost and Utilization Project National Inpatient Sample and the Medicare Hospital Outpatient Prospective Payment System. Investigators used secondary literature to inform model inputs.

Total cost of therapy included any costs associated with lymphodepletion, acquisition and infusion of CAR T-cells and management of acute adverse events.

The model also showed:

In this scenario, the model found patients who received CAR T-cell therapy in a nonacademic specialty oncology network setting would save $27,294 compared with the inpatient setting. In addition, in the scenario analysis the decrease in incremental cost reductions was associated with a lower overall incidence of AEs, which reduced the consequences of associated AE management costs, while the monitoring required at baseline was held constant.

The results indicate CAR T-cell therapy with a better safety profile may be more economical and could further leverage the outpatient site of care, researchers said. They concluded, The potential availability of CAR T-cell therapies with lower AE rates that are suitable for outpatient administration may reduce the total costs of care.

One limit to the study highlighted by the authors is the fact that outpatient administration may not be an option for all patients with LBCL.Eligibility can be contingent on the patients health status, support system, or the availability of housing near hospitals.

However, some specialists predict a gradual shift of all CAR T-cell therapies to the outpatient setting. Part of the reason for that [shift] is the way that it's reimbursed as an outpatient therapy is slightly more favorableso, financially it is better to do that, said John Sweetenham, MD, professor in the Department of Internal Medicine at UT Southwestern Medical Center and the Associate Director for Clinical Affairs at UTSWs Harold C. Simmons Comprehensive Cancer Center.

He continued, The problem is that these are very toxic treatments, and that many of the patients are not going to be manageable in the outpatient setting; but I do see that as one of the factors which is influencing a slow transition to outpatient CAR-Ts.

Expanded access to novel therapies in immune-oncology (IO) like CAR T-cell therapy also remains a priority among community level oncologists. Reimbursement, operational, and medical challenges associated with cellular therapy inhibit widespread uptake of the therapy, explained Lee Schwartzberg, MD, FACP, chief medical officer and board member at OneOncology. Only a small number of patients, frankly, have been treated with the first-generation CAR-T cells. So we need to develop new technologies and new operational models to do this, he said in an interview with The American Journal of Managed Care.

Reference

Lyman GH, Nguyen A, Snyder S, et al. Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma [published online April 6, 2020]. JAMA Netw Open. doi: 10.1001/jamanetworkopen.2020.2072.

More:
What Is The Economic Value of Receiving CAR T-Cell Therapy in an Outpatient Setting? - AJMC.com Managed Markets Network

For a few years now, scientists at Washington University have been working on techniques to turn stem cells into pancreatic beta cells as a way of addressing insulin shortages in diabetics. After some promising recent strides, the team is now reporting another exciting breakthrough, combining this technique with the CRISPR gene-editing tool to reverse the disease in mice.

The pancreas contains what are known as beta cells, which secrete insulin as a way of tempering spikes in blood-sugar levels. But in those with diabetes, these beta cells either die off or dont function as they should, which means sufferers have to rely on diet and or regular insulin injections to manage their blood-sugar levels instead.

One of the ways scientists are working to replenish these stocks of pancreatic beta cells is by making them out of human stem cells, which are versatile, blank slate-like cells that can mature into almost any type of cell in the human body. The Washington University team has operated at the vanguard of this technology with a number of key breakthroughs, most recently with a cell implantation technique that functionally cured mice with diabetes.

The researchers are continuing to press ahead in search of new and improved methods, and this led them to the CRISPR gene-editing system, which itself has shown real promise as a tool to treat diabetes. The hope was that CRISPR could be used to correct genetic defects leading to diabetes, combining with the stem cell therapy to produce even more effective results.

As a proof of concept, the scientists took skin cells from a patient with a rare genetic type of diabetes called Wolfram syndrome, which develops during childhood and typically involves multiple insulin injections each day. These skin cells were converted into induced pluripotent stem cells, which were in turn converted into insulin-secreting beta cells. But as an additional step, CRISPR was used to correct a genetic mutation that causes Wolfram syndrome.

These edited beta cells were then pitted against non-edited beta cells from the same batch in test tube experiments and in mice with a severe type of diabetes. The edited cells proved more efficient at secreting insulin and when implanted under the skin in mice, reportedly caused the diabetes to quickly disappear. The rodents that received the unedited beta cells remained diabetic.

This is the first time CRISPR has been used to fix a patients diabetes-causing genetic defect and successfully reverse diabetes, said co-senior investigator Jeffrey R. Millman. For this study, we used cells from a patient with Wolfram syndrome because, conceptually, we knew it would be easier to correct a defect caused by a single gene. But we see this as a stepping stone toward applying gene therapy to a broader population of patients with diabetes.

The researchers are now continuing to work on improving the beta cell production technique, which in the future could involve cells taken form the blood or even urine, rather than the skin. They believe that further down the track this therapy could prove useful in treating both type 1 and type 2 diabetes, by correcting mutations that arise from genetic and environmental factors, and possibly be used to treat other conditions, as well.

We basically were able to use these cells to cure the problem, making normal beta cells by correcting this mutation, said co-senior investigator Fumihiko Urano. Its a proof of concept demonstrating that correcting gene defects that cause or contribute to diabetes in this case, in the Wolfram syndrome gene we can make beta cells that more effectively control blood sugar. Its also possible that by correcting the genetic defects in these cells, we may correct other problems Wolfram syndrome patients experience, such as visual impairment and neurodegeneration.

The research was published in the journal Science Translational Medicine.

Source: Washington University

Original post:
CRISPR combines with stem cell therapy to reverse diabetes in mice - New Atlas

CAR-T and TCR-T therapies that involve engineering a patients own immune cells with antigen-specific receptors have revolutionized blood cancer treatment. Nowscientists at Duke-NUS Medical School are exploring the possibility of turning the approach against COVID-19.

The idea of using CAR/TCR-T cell therapy has already been proposed for treating chronic viral infections such as HIV and hepatitis B. Based on previous research, Antonio Bertoletti from Duke-NUS emerging infectious diseases research program suggest these immunotherapies might also be useful in treating SARS-CoV-2, the virus causing the current pandemic.

We demonstrated that T cells can be redirected to target the coronavirus responsible for SARS. Our team has now begun exploring the potential of CAR/TCR T cell immunotherapy for controlling the COVID-19-causing virus, SARS-CoV-2, and protecting patients from its symptomatic effects, Bertoletti said in a statement.

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

These types of therapies involve modifying patients' own T cells with either a chimeric antigen receptor (CAR) or a T-cell receptor (TCR) that can recognize specific antigens associated with cancer,and then guiding the immune cells to eradicate the targets when infused back into the patients.

In a 2011 article published in the Journal of Virology, Bertoletti led a team that generated TCR-T cells that can go after SARS, another coronavirus that caused a deadly outbreak in China and other countries in late 2002 and early 2003.

The team showed that those TCR-redirected T cells displayed a functional profile similar to that of SARS-specific memory CD8 T cells from people who recovered from SARS-CoV infection. Based on the findings, the researchers suggested that TCR-T cells represent a promising prophylactic or therapeutic treatment for SARS.

RELATED:How 'duoCAR-T' cells could clear HIV and prevent resurgence of virus reservoirs

CAR-T cells have been explored in other viruses. A research team from the Albert Einstein College of Medicine and the University of Pittsburgh, for example,designed duoCAR-T cells that target three sites on the HIV envelope glycoprotein. In the lab, the cell therapy eliminated up to 99% of immune cells infected with different strains of HIV.

Despite thepromise of T-cell therapies, however, Bertoletti and colleague Anthony Tanoto Tan cautioned about potential safety concerns of using them to treat viral infections affecting vital organs. For one thing, CAR-T treatments havebeen linked to the dangerous side effect called cytokine release syndrome, in which overreactive immune cells launch an inflammatory response that can destroy organs, they said in a recent Journal of Experimental Medicine commentary. Similar cytokine storm effects have been reported in somesevere COVID-19 patients, leading to potentially life-threatening lung inflammations.

[T]he infusion ofT cells stably expressingpathogen-specific CAR/TCR poses therisk that these T cells might proliferate and wipe out all the infected cells that might be the majority of the infected organ, Bertoletti and Tanoto Tan wrote in their article.

To addressthat problem, Bertoletti and colleagues are using mRNA electroporation to engineer CAR/TCR T cells, which they say can limit their inflammatory capability and shorten the functional activity. That may offer a safer way to use engineered immune cells to treat viral diseases.

Several organizations are also working on cell therapies for COVID-19. AlloVir and Baylor College of Medicine have teamed up to develop an off-the-shelf therapy that entails exposing donor T cells to cytokines combined with viral fragments so the new cells can target the novel coronavirus. Celgene spinoff Celularity just started clinical trial of its cancer treatment CYNK-001 for COVID-19. The drugturns placental stem cells into one-size-fits-all natural killer cells.

See more here:
Scientists explore using CAR-T and other engineered immune cells to target COVID-19 - FierceBiotech